Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody

Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody

A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine/tenofovir alafenamide to cabotegravir/rilpivir...

Full description

Bibliographic Details
Main Authors: Eisuke Adachi, Ayako Sedohara, Kotaro Arizono, Kazuaki Takahashi, Amato Otani, Yoshiaki Kanno, Makoto Saito, Michiko Koga, Hiroshi Yotsuyanagi
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2024-08-01
Series:Emerging Infectious Diseases
Subjects:
hepatitis B
hepatitis B virus
HIV
HBV
antiretroviral therapy
cabotegravir
Online Access:https://wwwnc.cdc.gov/eid/article/30/8/24-0019_article

Internet

https://wwwnc.cdc.gov/eid/article/30/8/24-0019_article

Similar Items